Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double-blinded Phase 1 Clinical Trial to Assess Safety, Tolerability and Reactogenicity of the Pan-Malaria Transmission-Blocking Vaccine AnAPN1 in Healthy Adults Living in Gabon

NCT05905432 is registered in ClinicalTrials.gov with Centre de Recherche Médicale de Lambaréné as lead sponsor.

NCT NCT05905432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05905432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double-blinded Phase 1 Clinical Trial to Assess Safety, Tolerability and Reactogenicity of the Pan-Malaria Transmission-Blocking Vaccine AnAPN1 in Healthy Adults Living in Gabon
Lead sponsor
Centre de Recherche Médicale de Lambaréné
Phase
Phase 1
Overall status
Completed
Start date
September 11, 2023
Completion date
January 31, 2025
Enrollment
33 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria